Affordable Medicines Europe welcomes the opportunity to contribute to the implementing rules on registration and reporting under Regulation (EU) 2025/40. We represent the independent distribution of medicines across the EEA, encompassing both the parallel import and export of medicines between EU Member States.
AME
Affordable Medicines Europe
Industry association · Belgium · EU Transparency Register 509882515669-01
4
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1518 trade and business associations on this site, they rank #726 by legislative files engaged, a count of participation, not a measure of influence.
3
declared lobbying FTE
self-declared
€500K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2015
in the register since
Declares membership of
- Affordable Medicines Europe is a member of:
- the European Medicines Verification Organisation (EMVO)
- the Alliance for Safe Online Pharmacy (ASOP EU)
- the Federation of European and International Associations (FAIB)
- Friends of Europe
- European Society of Association Executives (ESAE)
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Trade and business associations
- Head office
- Brussels, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Affordable in PolicySpeak: request access →
Work at Affordable Medicines Europe? so we know who speaks for it.
Their record over time
Affordable Medicines Europe filed 4 positions between 27 Apr 2021 and 10 Sept 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2021 · 1 filed2022 · 1 filed2026 · 2 filed
What they argued
The Single Market plays an important role in supporting access to affordable medical devices across the EU. By enabling their redistribution between Member States, from markets where there is a surplus to others where there is a need, it contributes to improved availability, a more efficient allocation of medical devices, and greater affordability through enhanced competition.
While we welcome the reforms and actions put forward by the Commission in this strategy, there is also a lack of ambition when it comes to expanding the use of the tools already available in the toolbox. This includes creating a better framework for the parallel import/distribution sector in order to deliver better affordability and access.
Affordable Medicines Europe welcomes the European Commission’s proposal of a new Single Market Emergency Instrument aimed to guarantee the free movement of goods, services, and people, with greater transparency and coordination during crises.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Affordable Medicines Europe next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 55.
Is this your organization?
Everything on this page comes from Affordable Medicines Europe’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.